Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma
Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to dete...
Gespeichert in:
| Veröffentlicht in: | The Egyptian journal of immunology 2024-01, Vol.31 (1), p.174-183 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 1 |
| container_start_page | 174 |
| container_title | The Egyptian journal of immunology |
| container_volume | 31 |
| creator | El-Batal, Heba M Kamel, Mahmoud M Moaz, Inas Gohar, Noha M |
| description | Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to determine whether IL-17A can be used as a biomarker for diagnosis of breast cancer. Therefore, we compared concentrations of serum IL-17A in patients suffering from breast carcinoma and normal control women by an enzyme-linked immunosorbent assay (ELISA). This study included 86 women, 44 patients that were diagnosed with breast carcinoma, and 42 normal control women. Serum IL-17A levels in both case and control groups were measured by sandwich ELISA kits. The IL-17A serum level was significantly higher among patients with breast carcinoma than in the control group (p |
| doi_str_mv | 10.55133/eji.310118 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2915571719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915571719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1998-98533798f9f53eb4fe9e9a93ef85fe86d5f9a9f9c089de7db13ca4a9407bcf6b3</originalsourceid><addsrcrecordid>eNpNkM9LwzAYhoMobsydvEuOgnTma5omOc4x52CgBz2XtP2Cmf0xk3ay_97ipnh63xce3sNDyDWwmRDA-T1u3YwDA1BnZAwALEo0i8__9RGZhrBljEEsZCrlJRlxFQ9dpmOyWu5N1ZvOtQ1tLV03HfoK-w_XRCDpnG5wj1WgrqEvA4RNF-iX697pg0cTOrowvnBNW5srcmFNFXB6ygl5e1y-Lp6izfNqvZhvogK0VpFWgnOpldVWcMwTixq10RytEhZVWgo7TKsLpnSJssyBFyYxOmEyL2ya8wm5Pf7ufPvZY-iy2oUCq8o02PYhizUIIUGCHtC7I1r4NgSPNtt5Vxt_yIBlP_KyQV52lDfQN6fjPq-x_GN_VfFvNlNpNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915571719</pqid></control><display><type>article</type><title>Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma</title><source>Alma/SFX Local Collection</source><creator>El-Batal, Heba M ; Kamel, Mahmoud M ; Moaz, Inas ; Gohar, Noha M</creator><creatorcontrib>El-Batal, Heba M ; Kamel, Mahmoud M ; Moaz, Inas ; Gohar, Noha M ; Department of Medical Microbiology & Immunology, Faculty of Medicine, Cairo University, Giza, Egypt</creatorcontrib><description>Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to determine whether IL-17A can be used as a biomarker for diagnosis of breast cancer. Therefore, we compared concentrations of serum IL-17A in patients suffering from breast carcinoma and normal control women by an enzyme-linked immunosorbent assay (ELISA). This study included 86 women, 44 patients that were diagnosed with breast carcinoma, and 42 normal control women. Serum IL-17A levels in both case and control groups were measured by sandwich ELISA kits. The IL-17A serum level was significantly higher among patients with breast carcinoma than in the control group (p <0.001). The serum IL-17A concentration was significantly higher in estrogen receptor-positive cases than in estrogen receptor-negative cases (p=0.033). The highest levels of IL-17A were detected in patients with stage 2 breast carcinoma rather than stage 3 with no significant correlation. There was no correlation between IL-17A level and tumor size, lymph node invasion, or metastasis in patients with breast cancer. In conclusion, a high level of IL-17A in breast carcinoma patients compared to the control group was detected in our study. It indicates that IL-17A could be a promising biomarker for diagnosis of breast cancer and may play a role in tumor development. High levels of IL-17A were not a predictor of poor prognosis in breast cancer patients as it was not related to tumor size, lymph node invasion, or metastasis.</description><identifier>ISSN: 1110-4902</identifier><identifier>EISSN: 1110-4902</identifier><identifier>DOI: 10.55133/eji.310118</identifier><identifier>PMID: 38225776</identifier><language>eng</language><publisher>Egypt</publisher><ispartof>The Egyptian journal of immunology, 2024-01, Vol.31 (1), p.174-183</ispartof><rights>Copyright© by the Egyptian Association of Immunologists.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38225776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Batal, Heba M</creatorcontrib><creatorcontrib>Kamel, Mahmoud M</creatorcontrib><creatorcontrib>Moaz, Inas</creatorcontrib><creatorcontrib>Gohar, Noha M</creatorcontrib><creatorcontrib>Department of Medical Microbiology & Immunology, Faculty of Medicine, Cairo University, Giza, Egypt</creatorcontrib><title>Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma</title><title>The Egyptian journal of immunology</title><addtitle>Egypt J Immunol</addtitle><description>Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to determine whether IL-17A can be used as a biomarker for diagnosis of breast cancer. Therefore, we compared concentrations of serum IL-17A in patients suffering from breast carcinoma and normal control women by an enzyme-linked immunosorbent assay (ELISA). This study included 86 women, 44 patients that were diagnosed with breast carcinoma, and 42 normal control women. Serum IL-17A levels in both case and control groups were measured by sandwich ELISA kits. The IL-17A serum level was significantly higher among patients with breast carcinoma than in the control group (p <0.001). The serum IL-17A concentration was significantly higher in estrogen receptor-positive cases than in estrogen receptor-negative cases (p=0.033). The highest levels of IL-17A were detected in patients with stage 2 breast carcinoma rather than stage 3 with no significant correlation. There was no correlation between IL-17A level and tumor size, lymph node invasion, or metastasis in patients with breast cancer. In conclusion, a high level of IL-17A in breast carcinoma patients compared to the control group was detected in our study. It indicates that IL-17A could be a promising biomarker for diagnosis of breast cancer and may play a role in tumor development. High levels of IL-17A were not a predictor of poor prognosis in breast cancer patients as it was not related to tumor size, lymph node invasion, or metastasis.</description><issn>1110-4902</issn><issn>1110-4902</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkM9LwzAYhoMobsydvEuOgnTma5omOc4x52CgBz2XtP2Cmf0xk3ay_97ipnh63xce3sNDyDWwmRDA-T1u3YwDA1BnZAwALEo0i8__9RGZhrBljEEsZCrlJRlxFQ9dpmOyWu5N1ZvOtQ1tLV03HfoK-w_XRCDpnG5wj1WgrqEvA4RNF-iX697pg0cTOrowvnBNW5srcmFNFXB6ygl5e1y-Lp6izfNqvZhvogK0VpFWgnOpldVWcMwTixq10RytEhZVWgo7TKsLpnSJssyBFyYxOmEyL2ya8wm5Pf7ufPvZY-iy2oUCq8o02PYhizUIIUGCHtC7I1r4NgSPNtt5Vxt_yIBlP_KyQV52lDfQN6fjPq-x_GN_VfFvNlNpNw</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>El-Batal, Heba M</creator><creator>Kamel, Mahmoud M</creator><creator>Moaz, Inas</creator><creator>Gohar, Noha M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202401</creationdate><title>Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma</title><author>El-Batal, Heba M ; Kamel, Mahmoud M ; Moaz, Inas ; Gohar, Noha M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1998-98533798f9f53eb4fe9e9a93ef85fe86d5f9a9f9c089de7db13ca4a9407bcf6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>El-Batal, Heba M</creatorcontrib><creatorcontrib>Kamel, Mahmoud M</creatorcontrib><creatorcontrib>Moaz, Inas</creatorcontrib><creatorcontrib>Gohar, Noha M</creatorcontrib><creatorcontrib>Department of Medical Microbiology & Immunology, Faculty of Medicine, Cairo University, Giza, Egypt</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Egyptian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Batal, Heba M</au><au>Kamel, Mahmoud M</au><au>Moaz, Inas</au><au>Gohar, Noha M</au><aucorp>Department of Medical Microbiology & Immunology, Faculty of Medicine, Cairo University, Giza, Egypt</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma</atitle><jtitle>The Egyptian journal of immunology</jtitle><addtitle>Egypt J Immunol</addtitle><date>2024-01</date><risdate>2024</risdate><volume>31</volume><issue>1</issue><spage>174</spage><epage>183</epage><pages>174-183</pages><issn>1110-4902</issn><eissn>1110-4902</eissn><abstract>Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to determine whether IL-17A can be used as a biomarker for diagnosis of breast cancer. Therefore, we compared concentrations of serum IL-17A in patients suffering from breast carcinoma and normal control women by an enzyme-linked immunosorbent assay (ELISA). This study included 86 women, 44 patients that were diagnosed with breast carcinoma, and 42 normal control women. Serum IL-17A levels in both case and control groups were measured by sandwich ELISA kits. The IL-17A serum level was significantly higher among patients with breast carcinoma than in the control group (p <0.001). The serum IL-17A concentration was significantly higher in estrogen receptor-positive cases than in estrogen receptor-negative cases (p=0.033). The highest levels of IL-17A were detected in patients with stage 2 breast carcinoma rather than stage 3 with no significant correlation. There was no correlation between IL-17A level and tumor size, lymph node invasion, or metastasis in patients with breast cancer. In conclusion, a high level of IL-17A in breast carcinoma patients compared to the control group was detected in our study. It indicates that IL-17A could be a promising biomarker for diagnosis of breast cancer and may play a role in tumor development. High levels of IL-17A were not a predictor of poor prognosis in breast cancer patients as it was not related to tumor size, lymph node invasion, or metastasis.</abstract><cop>Egypt</cop><pmid>38225776</pmid><doi>10.55133/eji.310118</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1110-4902 |
| ispartof | The Egyptian journal of immunology, 2024-01, Vol.31 (1), p.174-183 |
| issn | 1110-4902 1110-4902 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2915571719 |
| source | Alma/SFX Local Collection |
| title | Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Interleukin-17%20A%20Levels%20in%20Patients%20with%20Breast%20Carcinoma&rft.jtitle=The%20Egyptian%20journal%20of%20immunology&rft.au=El-Batal,%20Heba%20M&rft.aucorp=Department%20of%20Medical%20Microbiology%20&%20Immunology,%20Faculty%20of%20Medicine,%20Cairo%20University,%20Giza,%20Egypt&rft.date=2024-01&rft.volume=31&rft.issue=1&rft.spage=174&rft.epage=183&rft.pages=174-183&rft.issn=1110-4902&rft.eissn=1110-4902&rft_id=info:doi/10.55133/eji.310118&rft_dat=%3Cproquest_cross%3E2915571719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915571719&rft_id=info:pmid/38225776&rfr_iscdi=true |